Efficacy end points (after adjusting for age, sex, Killip class as covariates)
| End points | A (n=45) n (%) | B (n=155) n (%) | p Value | Relative risk | |
|---|---|---|---|---|---|
| Estimate | 95% CI | ||||
| Death, reinfarction, repeat revascularisation, cardiogenic shock, CHF | |||||
| At 30 days | 5 (11.1) | 6 (3.9) | 0.12 | 2.22 | 0.81 to 6.13 |
| At 3 months | 6 (13.3) | 9 (5.8) | 0.23 | 1.70 | 0.72 to 4.05 |
| At 6 months | 6 (13.3) | 11 (7.1) | 0.34 | 1.50 | 0.65 to 3.43 |
| At 1 year | 6 (13.3) | 14 (9.0) | 0.64 | 1.21 | 0.54 to 2.71 |
CHF, congestive heart failure.